Matthew P. Kosloski
Regeneron (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, Dermatology and Skin Diseases, Asthma and respiratory diseases, Hemophilia Treatment and Research, HIV/AIDS drug development and treatment
Most-Cited Works
- → Delivery of Therapeutic Proteins(2010)527 cited
- → Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis(2022)422 cited
- → Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment(2017)395 cited
- → Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial(2022)244 cited
- → A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis(2019)205 cited
- → Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study(2018)144 cited
- → Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)(2022)109 cited
- → Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age(2024)93 cited
- → A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy(2020)85 cited
- → Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study(2020)84 cited